STOCK TITAN

ANTIBE THERAPEUTICS INC - $ATBPF STOCK NEWS

Welcome to our dedicated page for ANTIBE THERAPEUTICS news (Ticker: $ATBPF), a resource for investors and traders seeking the latest updates and insights on ANTIBE THERAPEUTICS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANTIBE THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANTIBE THERAPEUTICS's position in the market.

Rhea-AI Summary
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) successfully completed a PK/PD study for otenaproxesul’s new formulation, with Phase II initiation on track for the upcoming quarter. The company ended the quarter with $28 million in cash and equivalents. The PK/PD study results validated the liver safety of the new formulation, and the company is upgrading the design of the upcoming Phase II trial based on the strong safety and PK data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
-
Rhea-AI Summary
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announces positive pharmacokinetic results for otenaproxesul's faster-absorbing formulation, confirming safety and informing future treatment regimens for the upcoming Phase II trial. The study delivers crucial data for the trial, on track to launch in Q1 2024, and complements strong safety data previously reported. The results confirm linear, dose-proportional pharmacokinetics and lower doses needed to achieve target plasma levels compared to the original formulation, expanding the drug's safety envelope.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.62%
Tags
-
Rhea-AI Summary
Antibe Therapeutics Inc. has completed the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. The study confirmed the drug's safety and will inform treatment regimens for the upcoming Phase II trial. All treatments were well tolerated with no adverse safety signals or elevations in liver enzymes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.3%
Tags
Rhea-AI Summary
Antibe Therapeutics initiates PK/PD study for otenaproxesul's faster-absorbing formulation for acute pain
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
-
Rhea-AI Summary
Antibe Therapeutics receives Health Canada's approval to initiate PK/PD study for otenaproxesul's faster-absorbing formulation, setting the stage for Phase II trial in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Summary
Antibe Therapeutics announces positive results of annual meeting of shareholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
ANTIBE THERAPEUTICS INC

OTC:ATBPF

ATBPF Rankings

ATBPF Stock Data

11.43M
49.38M
7.94%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Toronto